Onychomycosis Market Insight

DelveInsight’s ‘Onychomycosis – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Onychomycosis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), China and Japan.

 

The Onychomycosis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Onychomycosis symptoms market size from 2018 to 2030. The report also covers current Onychomycosis symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5
  • Japan
  • China

Study Period: 2018–2030

Onychomycosis Disease Understanding and Treatment Algorithm

Onychomycosis Overview

Onychomycosis is a common fungal nail infection that has been estimated to account for about half of all nail diseases. Although not life-threatening, fungal nail infections are an important public health concern due to their high prevalence, poor response to therapy, and significant clinical, social and financial impact.

 

In Western countries, 80–90% of Onychomycosis cases are primarily caused by dermatophytes, with 5–17% due to yeasts and 2–3% due to non-dermatophyte molds. The high prevalence of fungal infections in North America is largely due to the immigration of dermatophytes from other areas of the world, such as West Africa and Southeast Asia.

 

Patients with Onychomycosis often complain of nail discoloration, nail separation, brittleness, or thickening that often worsens with time. A history of tinea pedis or hyperhidrosis of the feet is common. Nails affected by Onychomycosis may cause local pain, difficulty fitting shoes and employment, social embarrassment, and harm the quality of life.

 

Greater than 50% nail plate involvement, more than three nails involved, or presence of dermatophytosis, requires consideration of systemic therapy. Oral terbinafine (continuous or pulse) is usually the first choice of therapy. However, if there is less than 50% involvement of the diseased nail plate and less than three nails involved, topical therapy is an appropriate consideration. Efinaconazole 10%, ciclopirox 8% (once a day), amorolfine 5% (once a week), or tavaborole 5% are the preferred topical treatment options.

 

Onychomycosis Diagnosis and Treatment

It covers conventional and current medical therapies and diagnosis available in the Onychomycosis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the G8.

 

The DelveInsight Onychomycosis market report thoroughly understands Onychomycosis symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Onychomycosis symptoms of treatment algorithms and treatment guidelines for Onychomycosis symptoms in the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan.

Onychomycosis Epidemiology

The epidemiology division’s Onychomycosis symptoms provide insights into the historical and current patient pool and the forecasted trend for every G8 countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Onychomycosis epidemiology segmented as the Diagnosed Prevalent Cases of Onychomycosis, Diagnosed Prevalent by Subtypes, Diagnosed Prevalent Cases of Onychomycosis by Severity, and Treated Cases of Onychomycosis. The report includes the prevalent Onychomycosis symptoms in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), China, and Japan from 2018 to 2030.

 

The total prevalent cases of Onychomycosis in the G8 were 93,633,252 in 2020.

Onychomycosis Drug Chapters

The drug chapter segment of the Onychomycosis report encloses the detailed analysis of Onychomycosis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Onychomycosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

The current treatment landscape can be divided into components based on routes of administration, namely; Systemic (Oral) and Topical Medications.

 

Currently, oral Terbinafine hydrochloride (Lamisil) is the most common treatment for Onychomycosis. These 250mg tablets are taken once a day for 12 weeks. First approved in 1996 by the US FDA, it has been the mainstay with all its generic versions marketed since the patent expiry in 2007. Other components that make up the total revenue generated by systemic therapies include Itraconazole, Griseofulvin, Fluconazole, and Ketoconazole. These components have been included in the forecast model to calculate the approximate revenue estimates during the study period [2018–2030].

Products detail in the report…

 

Onychomycosis Emerging Drugs

 

One major player is Moberg Pharma, with its leading product MOB-015. It is a next-generation nail fungus treatment targeting both the over-the-counter (OTC) and prescription markets. The company’s patented technology facilitates the delivery of high concentrations of terbinafine into and through the nail. Therefore, this compound has generated enough buzz already in the market since it can address the unmet need for better topical treatments without the risk of systemic side effects.

Onychomycosis Market Outlook

The Onychomycosis market outlook of the report helps build the detailed comprehension of the historic, current, and forecasted Onychomycosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of Onychomycosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight clearly.

 

According to DelveInsight, the Onychomycosis market in the G8 is expected to change in the study period 2018–2030.

 

Key Findings

This section includes a glimpse of the Onychomycosis market in the United States. The market size of Onychomycosis in G8 was USD 1,278.4 Million in 2020, and the market is estimated to increase during the study period (2018–2030).

 

The United States Market Outlook

This section provides a total of Onychomycosis market size and market size by therapies in the United States.

 

The pipeline scenario is showing early promise with several therapeutic candidates at different stages of clinical development. Many new therapies for Onychomycosis are in development, many of which have novel targets and mechanisms of action. Among the biologics, Blueberry Therapeutics’ BB2603 and Mycovia Pharmaceuticals’ VT-1161 are in the late development stages.

 

Blueberry Therapeutics’ drug candidate, BB2603, has received investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development to treat Onychomycosis. The company uses its potent nanotechnology-based topical drug delivery platform to maintain the efficacy of the oral gold standard treatment but at a lower dose. Targeted delivery by penetrating the nail bed ensures lower dosage and reduced systemic side effects.

 

EU-5 Countries: Market Outlook

The total Onychomycosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided.

 

Novexatin (NP213) being developed by NovaBiotics, is another such candidate whose developmental status is currently under speculation due to certain technological developments. Although the active compound NP213 is a novel, synthetic antimicrobial peptide (AMP) generated from NovaBiotics’ rational drug design technology platform and have demonstrated safety and efficacy profiles as per company’s reports, the mutual termination of a license agreement with Taro Pharmaceuticals in 2018 has cast a shadow on its developmental pathway. 

 

Japan: Market Outlook

The total Onychomycosis market size and market size by therapies in Japan are also mentioned.

Onychomycosis Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Onychomycosis market uptake by drugs, patient uptake by therapies, and drug sales.

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows comparing the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Onychomycosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses Onychomycosis key players involved in developing targeted therapeutics.

 

Major players include Blueberry Therapeutics’ BB2603 and Moberg Pharma’s MOB-015 being assessed as potential therapies available in the market in the future.

 

Products detail in the report…

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Onychomycosis emerging therapies.

Reimbursement Scenario in Onychomycosis

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do their best to ensure that the patient receives Social Security Disability benefits as quickly as possible and help the patient avoid the lengthy disability appeal process.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinions working in Onychomycosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Onychomycosis market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Onychomycosis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Onychomycosis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Onychomycosis epidemiology and treatment in the  United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan
  • Additionally, an all-inclusive account of both the current and emerging therapies for Onychomycosis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Onychomycosis market; historical and forecasted is included in the report, covering drug outreach in the United States, EU5 (Germany, Spain, France, Italy, UK), China and Japan
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Onychomycosis market

Report Highlights

  • In the coming years, the Onychomycosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Onychomycosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Onychomycosis. The launch of emerging therapies will significantly impact the Onychomycosis market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Onychomycosis.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Onychomycosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Onychomycosis Pipeline Analysis
  • Onychomycosis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Onychomycosis Report Key Strengths

  • 10-Year Forecast
  • G8 Countries Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Market Size by Country
  • Market Size by Therapy

Onychomycosis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Emerging Drug Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Onychomycosis Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the Onychomycosis total market size and market size by therapies across the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan during the forecast period (2018–2030)?
  • What are the market’s key findings across the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan, and historical as well as forecasted epidemiology during the forecast period (2018–2030)?
  • At what CAGR, the Onychomycosis market is expected to grow by the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan during the forecast period (2018–2030)?
  • What would be the Onychomycosis market outlook across the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan during the forecast period (2018–2030)?
  • What would be the Onychomycosis market growth till 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Onychomycosis?
  • What is the historical Onychomycosis patient pool in the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan?
  • What would be the forecasted patient pool of Onychomycosis in the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan?
  • What will be the growth opportunities in the G8 concerning the patient population about Onychomycosis?
  • At what CAGR is the population expected to grow during the forecast period (2018–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Onychomycosis?
  • What are the current treatment guidelines for treating Onychomycosis in the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan?
  • What are Onychomycosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Onychomycosis?
  • How many therapies are developed by each company for the treatment of Onychomycosis?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Onychomycosis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Onychomycosis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Onychomycosis and its status?
  • What are the key designations that have been granted for the emerging therapies for Onychomycosis?
  • What are the global historical and forecasted market of Onychomycosis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Onychomycosis market
  • To understand the future market competition in the Onychomycosis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Onychomycosis in the United States, EU5 (Germany, Spain, France, Italy, UK), China, and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Onychomycosis market
  • To understand the future market competition in the Onychomycosis market

1. Key Insights

2. Report Introduction

3. Onychomycosis Market Overview at a Glance

3.1. Market Share (%) Distribution of Onychomycosis in 2018

3.2. Market Share (%) Distribution of Onychomycosis in 2030

4. Executive Summary of Onychomycosis

5. Disease Background and Overview

5.1. Introduction

5.2. Etiology and Risk Factors

5.3. Pathophysiology

5.4. Types

5.5. Clinical Aspects

5.6. Clinical Presentation and Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. G8 Total Prevalent Patient Population of Onychomycosis

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Diagnosed Prevalent Cases of Onychomycosis

6.4.2. Diagnosed Prevalent Cases of Onychomycosis by subtype

6.4.3. Diagnosed Prevalence of Onychomycosis by Severity

6.4.4. Treated cases of Onychomycosis

6.5. EU5

6.5.1. Germany

6.5.1.1. Diagnosed Prevalent Cases of Onychomycosis

6.5.1.2. Diagnosed Prevalent Cases of Onychomycosis by Subtype

6.5.1.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.5.1.4. Treated cases of Onychomycosis

6.5.2. France

6.5.2.1. Diagnosed Prevalent Cases of Onychomycosis

6.5.2.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.5.2.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.5.2.4. Treated Cases of Onychomycosis

6.5.3. Italy

6.5.3.1. Diagnosed Prevalent Cases of Onychomycosis

6.5.3.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.5.3.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.5.3.4. Treated Cases of Onychomycosis

6.5.4. Spain

6.5.4.1. Diagnosed Prevalent Cases of Onychomycosis

6.5.4.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.5.4.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.5.4.4. Treated Cases of Onychomycosis

6.5.5. United Kingdom

6.5.5.1. Diagnosed Prevalent Cases of Onychomycosis

6.5.5.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.5.5.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.5.5.4. Treated Cases of Onychomycosis

6.6. Japan

6.6.1. Diagnosed Prevalent Cases of Onychomycosis

6.6.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.6.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.6.4. Treated Cases of Onychomycosis

6.7. China

6.7.1. Diagnosed Prevalent Cases of Onychomycosis

6.7.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.7.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.7.4. Treated Cases of Onychomycosis

7. Treatment and Management

7.1. Treatment Algorithm

7.2. Management of Onychomycosis

7.3. Resistance of Dermatophytes to Standard Treatments

8. Treatment Guidelines

8.1. British Association of Dermatologists’ (BAD) guidelines for the management of onychomycosis

9. Patient Journey

10. Case Reports

11. Marketed Therapies

11.1. Kerydin (tavaborole): Pfizer

11.1.1. Product Description

11.1.2. Mechanism of action

11.1.3. Regulatory Milestones

11.1.4. Safety and Efficacy

11.1.5. Product Profile

11.2. Jublia/Clenafin (efinaconazole): Bausch Health

11.2.1. Product Description

11.2.2. Mechanism of action

11.2.3. Regulatory Milestones

11.2.4. Safety and Efficacy

11.2.5. Product Profile

11.3. Luliconazole: Sato Pharmaceutical/Bausch Health

11.3.1. Product Description

11.3.2. Mechanism of Action

11.3.3. Regulatory Milestones

11.3.4. Safety and Efficacy

11.3.5. Product Profile

11.4. Nialin: Sato Pharmaceutical/Eisai

11.4.1. Product Description

11.4.2. Mechanism of Action

11.4.3. Regulatory Milestones

11.4.4. Safety and Efficacy

11.4.5. Product Profile

12. Emerging Therapies

12.1. MOB015: Moberg Pharma

12.1.1. Drug Description

12.1.2. Regulatory Milestones

12.1.3. Clinical Development

12.1.3.1. Clinical Trials Information

12.1.4. Safety and Efficacy

12.1.5. Product Profile

12.2. BB2603: Blueberry Therapeutics

12.2.1. Drug Description

12.2.2. Regulatory Milestones

12.2.3. Clinical Development

12.2.3.1. Clinical Trials Information

12.2.4. Product Profile

12.3. VT-1161: Mycovia Pharmaceuticals

12.3.1. Drug Description

12.3.2. Regulatory Milestones

12.3.3. Clinical Development

12.3.3.1. Clinical Trials Information

12.3.4. Safety and Efficacy

12.3.5. Product Profile

12.4. ME1111: Meiji Seika Pharma

12.4.1. Drug Description

12.4.2. Clinical Development

12.4.2.1. Clinical Trials Information

12.4.3. Product Profile

12.5. NP213 (Novexatin): NovaBiotics

12.5.1. Drug Description

12.5.2. Regulatory Milestones

12.5.3. Clinical Development

12.5.3.1. Clinical Trials Information

12.5.4. Safety and Efficacy

12.5.5. Product Profile

12.6. HTS-519: Hallux

12.6.1. Drug Description

12.6.2. Clinical Development

12.6.2.1. Clinical Trials Information

12.6.3. Product Profile

12.7. P3058: Almirall

12.7.1. Drug Description

12.7.2. Regulatory Milestones

12.7.3. Clinical Development

12.7.3.1. Clinical Trials Information

12.7.4. Safety and Efficacy

12.7.5. Product Profile

12.8. PD P 506 A: Photonamic

12.8.1. Drug Description

12.8.2. Clinical Development

12.8.2.1. Clinical Trials Information

12.8.3. Product Profile

12.9. KP-607: Kaken Pharmaceuticals

12.9.1. Drug Description

12.9.2. Clinical Development

12.9.2.1. Clinical Trials Information

12.9.3. Product Profile

13. Onychomycosis: 7 Major Market Analysis

13.1. Key Findings

13.2. Market Size of Onychomycosis in G8 countries

14. Country-wise Market Analysis

14.1. Market Outlook

14.2. United States Market Size

14.2.1. Total Market Size of Onychomycosis by class

14.2.2. Market Size of Onychomycosis by Emerging Therapies

14.3. EU-5 Countries

14.3.1. Germany

14.3.1.1. Total Market Size of Onychomycosis by class

14.3.1.2. Market Size of Onychomycosis by Emerging Therapies

14.3.2. France

14.3.2.1. Total Market Size of Onychomycosis by class

14.3.2.2. Market Size of Onychomycosis by Emerging Therapies

14.3.3. Italy

14.3.3.1. Total Market Size of Onychomycosis by class

14.3.3.2. Market Size of Onychomycosis by Emerging Therapies

14.3.4. Spain

14.3.4.1. Total Market Size of Onychomycosis by class

14.3.4.2. Market Size of Onychomycosis by Emerging Therapies

14.3.5. United Kingdom

14.3.5.1. Total Market Size of Onychomycosis by class

14.3.5.2. Market Size of Onychomycosis by Emerging Therapies

14.4. Japan

14.4.1. Total Market Size of Onychomycosis by class

14.4.2. Market Size of Onychomycosis by Emerging Therapies

14.5. China

14.5.1. Total Market Size of Onychomycosis by class

14.5.2. Market Size of Onychomycosis by Emerging Therapies

15. KOL Views

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Unmet Needs

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of Onychomycosis, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Prevalent Patient Population of Onychomycosis in the G8 (2018–2030)

Table 3: Diagnosed Prevalent Cases of Onychomycosis in the US (2018–2030)

Table 4: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in the US (2018–2030)

Table 5: Diagnosed Prevalent Cases of Onychomycosis by Severity in the US (2018–2030)

Table 6: Treated Cases of Onychomycosis in the US (2018–2030)

Table 7: Diagnosed Prevalent Cases of Onychomycosis in Germany (2018–2030)

Table 8: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Germany (2018–2030)

Table 9: Diagnosed Prevalent of Onychomycosis by Severity in Germany (2018–2030)

Table 10: Treated Cases of Onychomycosis in Germany (2018–2030)

Table 11: Diagnosed Prevalent Cases of Onychomycosis in France (2018–2030)

Table 12: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in France (2018–2030)

Table 13: Diagnosed Prevalent Cases of Onychomycosis by Severity in France (2018–2030)

Table 14: Treated Cases of Onychomycosis in France (2018–2030)

Table 15: Diagnosed Prevalent Cases of Onychomycosis in Italy (2018–2030)

Table 16: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Italy (2018–2030)

Table 17: Diagnosed Prevalent Cases of Onychomycosis by Severity in Italy (2018–2030)

Table 18: Treated Cases of Onychomycosis in Italy (2018–2030)

Table 19: Diagnosed Prevalent Cases of Onychomycosis in Spain (2018–2030)

Table 20: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Spain (2018–2030)

Table 21: Diagnosed Prevalent Cases of Onychomycosis by Severity in Spain (2018–2030)

Table 22: Treated Cases of Onychomycosis in Spain (2018–2030)

Table 23: Diagnosed Prevalent Cases of Onychomycosis in the UK (2018–2030)

Table 24: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in the UK (2018–2030)

Table 25: Diagnosed Prevalent Cases of Onychomycosis by Severity in the UK (2018–2030)

Table 26: Treated Cases of Onychomycosis in the UK (2018–2030)

Table 27: Diagnosed Prevalent Cases of Onychomycosis in Japan (2018–2030)

Table 28: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Japan (2018–2030)

Table 29: Diagnosed Prevalent Cases of Onychomycosis by Severity in Japan (2018–2030)

Table 30: Treated Cases of Onychomycosis in Japan (2018–2030)

Table 31: Diagnosed Prevalent Cases of Onychomycosis in China (2018–2030)

Table 32: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in China (2018–2030)

Table 33: Diagnosed Prevalent Cases of Onychomycosis by Severity in China (2018–2030)

Table 34: Treated Cases of Onychomycosis in China (2018–2030)

Table 35: Summary of Drug Therapies in Children (Age 1–12 Years)

Table 36: Summary of Drug Therapies in Adults

Table 37: MOB015, Clinical Trial Description, 2021

Table 38: BB2603, Clinical Trial Description, 2021

Table 39: VT-1161, Clinical Trial Description, 2021

Table 40: ME1111, Clinical Trial Description, 2021

Table 41: NP213, Clinical Trial Description, 2021

Table 43: P3058, Clinical Trial Description, 2021

Table 45: KP-607, Clinical Trial Description, 2021

Table 42: HTS-519, Clinical Trial Description, 2021

Table 44: PD P 506 A, Clinical Trial Description, 2021

Table 46: G8 Market Size of Onychomycosisin USD Million (2018–2030)

Table 47: US Market Size of Onychomycosis by class in USD Million (2018–2030)

Table 48: US Market Size of Onychomycosis by Emerging Therapies in USD Million (2018–2030)

Table 49: Germany Market Size of Onychomycosis by class in USD Million (2018–2030)

Table 50: Germany Market Size of Onychomycosis by Emerging Therapies in USD Million (2018–2030)

Table 51: France Market Size of Onychomycosis by class in USD Million (2018–2030)

Table 52: France Market Size of Onychomycosis by Emerging Therapies in USD Million (2018–2030)

Table 53: Italy Market Size of Onychomycosis by class in USD Million (2018–2030)

Table 54: Italy Market Size of Onychomycosis by Emerging Therapies in USD Million (2018–2030)

Table 55: Spain Market Size of Onychomycosis by class in USD Million (2018–2030)

Table 56: Spain Market Size of Onychomycosis by Emerging Therapies in USD Million (2018–2030)

Table 57: UK Market Size of Onychomycosis by class in USD Million (2018–2030)

Table 58: UK Market Size of Onychomycosis by Emerging Therapies in USD Million (2018–2030)

Table 59: Japan Market Size of Onychomycosis by class in USD Million (2018–2030)

Table 60: Japan Market Size of Onychomycosis by Emerging Therapies in USD Million (2018–2030)

Table 61: China Market Size of Onychomycosis by class in USD Million (2018–2030)

Table 62: China Market Size of Onychomycosis by Emerging Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Prevalent Cases of Onychomycosis in the G8 Countries in thousands (2018–2030)

Figure 2: Diagnosed Prevalent Cases of Onychomycosis in the US in thousands (2018–2030)

Figure 3: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in the US in thousands (2018–2030)

Figure 4: Diagnosed Prevalent Cases of Onychomycosis by Severity in the US in thousands (2018–2030)

Figure 5: Treated Cases of Onychomycosis in the US in thousands (2018–2030)

Figure 6: Diagnosed Prevalent Cases of Onychomycosis in Germany in thousands (2018–2030)

Figure 7: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Germany in thousands (2018–2030)

Figure 8: Diagnosed Prevalent Cases of Onychomycosis by Severity in Germany in thousands (2018–2030)

Figure 9: Treated Cases of Onychomycosis in Germany in thousands (2018–2030)

Figure 10: Diagnosed Prevalent Cases of Onychomycosis in France in thousands (2018–2030)

Figure 11: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in France in thousands (2018–2030)

Figure 12: Diagnosed Prevalent Cases of Onychomycosis by Severity in France in thousands (2018–2030)

Figure 13: Treated Cases of Onychomycosis in France in thousands (2018–2030)

Figure 14: Diagnosed Prevalent Cases of Onychomycosis in Italy in thousands (2018–2030)

Figure 15: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Italy in thousands (2018–2030)

Figure 16: Diagnosed Prevalent Cases of Onychomycosis by Severity in Italy in thousands (2018–2030)

Figure 17: Treated Cases of Onychomycosis in Italy in thousands (2018–2030)

Figure 18: Diagnosed Prevalent Cases of Onychomycosis in Spain in thousands (2018–2030)

Figure 19: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Spain in thousands (2018–2030)

Figure 20: Diagnosed Prevalent Cases of Onychomycosis by Severity in Spain in thousands (2018–2030)

Figure 21: Treated Cases of Onychomycosis in Spain in thousands (2018–2030)

Figure 22: Diagnosed Prevalent Cases of Onychomycosis in the UK in thousands (2018–2030)

Figure 23: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in the UK in thousands (2018–2030)

Figure 24: Diagnosed Prevalent Cases of Onychomycosis by Severity in the UK in thousands (2018–2030)

Figure 25: Treated Cases of Onychomycosis in the UK in thousands (2018–2030)

Figure 26: Diagnosed Prevalent Cases of Onychomycosis in Japan in thousands (2018–2030)

Figure 27: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Japan in thousands (2018–2030)

Figure 28: Diagnosed Prevalent Cases of Onychomycosis by Severity in Japan in thousands (2018–2030)

Figure 29: Treated Cases of Onychomycosis in Japan in thousands (2018–2030)

Figure 30: Diagnosed Prevalent Cases of Onychomycosis in China in thousands (2018–2030)

Figure 31: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in China in thousands (2018–2030)

Figure 32: Diagnosed Prevalent Cases of Onychomycosis by Severity in China in thousands (2018–2030)

Figure 33: Treated Cases of Onychomycosis in China in thousands (2018–2030)

Figure 34: Algorithm to Guide Choice of Therapies in Onychomycosis

Figure 35: G8 Market Size of Onychomycosis in USD Million (2018–2030)

Figure 36: US Market Size of Onychomycosis by class, USD Million (2018–2030)

Figure 37: US Market Size of Onychomycosis by Emerging Therapies in USD Million

Figure 38: Germany Market Size of Onychomycosis by class, USD Million (2018–2030)

Figure 39: Germany Market Size of Onychomycosis by Emerging Therapies in USD Million

Figure 40: France Market Size of Onychomycosis by class, USD Million (2018–2030)

Figure 41: France Market Size of Onychomycosis by Emerging Therapies in USD Million

Figure 42: Italy Market Size of Onychomycosis by class, USD Million (2018–2030)

Figure 43: Italy Market Size of Onychomycosis by Emerging Therapies in USD Million

Figure 44: Spain Market Size of Onychomycosis by class, USD Million (2018–2030)

Figure 45: Spain Market Size of Onychomycosis by Emerging Therapies in USD Million

Figure 46: UK Market Size of Onychomycosis by class, USD Million (2018–2030)

Figure 47: UK Market Size of Onychomycosis by Emerging Therapies in USD Million

Figure 48: Japan Market Size of Onychomycosis by class, USD Million (2018–2030)

Figure 49: Japan Market Size of Onychomycosis by Emerging Therapies in USD Million

Figure 50: China Market Size of Onychomycosis by class, USD Million (2018–2030)

Figure 51: China Market Size of Onychomycosis by Emerging Therapies in USD Million

Pfizer
Bausch Health
Sato Pharmaceutical
Eisai
Moberg Pharma
Blueberry Therapeutics
Mycovia Pharmaceuticals
Meiji Seika Pharma
NovaBiotics
Hallux
Almirall
Photonamic
Kaken Pharmaceuticals

 

  • Tags:
  • Onychomycosis market
  • Onychomycosis market research
  • Onychomycosis market insight
  • Onychomycosis market trends
  • Onychomycosis market forecast
  • Onychomycosis market share
  • Onychomycosis pipeline drugs
  • Onychomycosis treatment algorithm
  • Onychomycosis drugs
  • Onychomycosis sales forecasting
  • Onychomycosis market size
  • Onychomycosis disease
  • Onychomycosis epidemiology
  • Onychomycosis

Forward to Friend

Need A Quote